1. In this randomized trial, upadacitinib dosed at 15mg with a 26-week glucocorticoid taper showed superior efficacy than placebo with...
1. In this randomized trial, obinutuzumab plus standard therapy was more efficacious than standard therapy alone in providing a complete...
1. The risk of tuberculosis (TB) was higher in individuals with obstructive or restrictive lung function impairment compared to those...
1. Influenza vaccine given alone or concurrently with a COVID-19 vaccine was associated with a small (< 1 day) but...
Alcohol Use Disorder Diagnoses Among Individuals Who Take HIV Preexposure Prophylaxis 1. In this cohort of individuals taking preexposure prophylaxis...
1. The risk of bloodstream infections (BSIs) in individuals with indwelling peripheral intravenous catheters (PIVCs) is significantly increased after 3...
1. In this randomized controlled trial, inebilizumab, an anti-CD19 monoclonal antibody, reduced the risk of flares and increased the likelihood...
1. CDASI-A score at 12 weeks was significantly lower in dazukibart 600 mg versus placebo, suggesting reduced morbidity. 2. Treatment-related...
1. The composite of patient-reported clinical response and endoscopic response was significantly greater in mirikizumab versus placebo. 2. Clinical remission...
1. The use of fecal microbiota, live-jslm (RBL; REBYOTA®) in the prevention of recurrent Clostridioides difficile infection (rCDI) in patients...
